Cargando…
Migratory Engineering of T Cells for Cancer Therapy
Adoptive cell therapy (ACT) and chimeric antigen receptor (CAR) T cell therapy in particular represents an adaptive, yet versatile strategy for cancer treatment. Convincing results in the treatment of hematological malignancies have led to FDA approval for several CAR T cell therapies in defined ref...
Autores principales: | Michaelides, Stefanos, Obeck, Hannah, Kechur, Daryna, Endres, Stefan, Kobold, Sebastian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9692862/ https://www.ncbi.nlm.nih.gov/pubmed/36366354 http://dx.doi.org/10.3390/vaccines10111845 |
Ejemplares similares
-
Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy
por: Lorenzini, Theo, et al.
Publicado: (2023) -
CAR T cell therapy in solid tumors: a short review
por: Umut, Öykü, et al.
Publicado: (2021) -
Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
por: Stock, Sophia, et al.
Publicado: (2022) -
Therapeutic Strategies for Targeting IL-1 in Cancer
por: Gottschlich, Adrian, et al.
Publicado: (2021) -
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
por: Stoiber, Stefan, et al.
Publicado: (2019)